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In this position statement, developed by The International 
College of Obsessive-Compulsive Spectrum Disorders, 
a group of international experts responds to recent 
developments in the evidence-based management 
of obsessive-compulsive disorder (OCD). The article 
presents those selected therapeutic advances judged 
to be of utmost relevance to the treatment of OCD, 
based on new and emerging evidence from clinical and 
translational science. Areas covered include refinement 
in the methods of clinical assessment, the importance of 
early intervention based on new staging models and the 
need to provide sustained well-being involving effective 
relapse prevention. The relative benefits of psychological, 
pharmacological and somatic treatments are reviewed 
and novel treatment strategies for difficult to treat OCD, 
including neurostimulation, as well as new areas for 
research such as problematic internet use, novel digital 
interventions, immunological therapies, pharmacogenetics 
and novel forms of psychotherapy are discussed. Int Clin 
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Introduction
Once a neglected illness, obsessive-compulsive disor-
der (OCD) is now recognized as a common, highly disa-
bling and potentially treatable early-onset brain disorder. 
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Clinical and translational research in OCD grows apace, 
and over the past 10  years has contributed to substan-
tial advances in understanding of the phenomenology, 
brain-based biology and treatment response, leading to 
innovations in nosological conceptualizations, therapeu-
tic interventions and services. Recent changes in the 
DSM-5 (American Psychiatric Association, 2013) and 
ICD-11 (WHO, 2018) diagnostic classification systems 
have set OCD at the head of a new family of obses-
sive-compulsive spectrum disorders [otherwise known 
as Obsessive-Compulsive or Related Disorders, or, 
Obsessive-Compulsive and Related Disorders (OCRDs)], 
including body dysmorphic, hoarding, hair-pulling, skin 
picking and olfactory reference disorders and hypochon-
driasis, all sharing compulsive behaviour as a cardinal 
characteristic. Serotonin reuptake inhibitors [selective 
serotonin reuptake inhibitors (SSRIs), clomipramine] or 
cognitive behavioural therapy (CBT) involving exposure 
and response prevention (ERP), represent the mainstay 
of contemporary treatment for OCD, with emerging 
evidence suggesting that early intervention produces 
better outcomes (Fineberg et al., 2019). However, a sub-
stantial minority of patients still fail to respond either in 
any meaningful way, or in terms of residual symptoms. 
Treatment-resistant OCD has become a fruitful research 
focus for clinical treatment and specialist services devel-
opment, worldwide.
A number of evidence-based clinical guidelines for man-
aging OCD have been published (Bandelow et al., 2012; 
Baldwin et al., 2014; Sookman et al., 2015). However, 
recent feedback from topic experts and stakeholders 
(National Institute for Health and Care Excellence, 
2019) has identified the need for an update, highlight-
ing that clinical practice has progressed in many areas. 
This includes evidence of efficacy for new pharmaco-
logical interventions and augmentation therapies among 
treatment-resistant groups, advances in invasive and 
noninvasive neurostimulation technology as well as rapid 
advances in information technology and telecommuni-
cations and the introduction of technology-enhanced 
interventions. Yet, in many parts of the world, access to 
recommended treatments and specialist care services, in 
particular for children, remains limited.
The International College of Obsessive-Compulsive 
Spectrum Disorders (ICOCS; www.ICOCS.org) is a 
global network of expert clinicians, researchers and 
‘experts by experience of OCD’, whose principal objec-
tive is to support and stimulate the study and treatment 
of obsessive-compulsive spectrum disorders. In recog-
nition of the need for updated clinical guidance on the 
treatment of OCD, the ICOCS has developed this posi-
tion statement, based on expert consensus and including 
a balanced representation of genders, child versus adult 
psychiatrists and early career scientists, with global and 
ethnic diversity. Agreement was reached on the key issues 
to be covered at a series of meetings, and the authors of 
each section were chosen based on their expertise in that 
area. An initial draft was prepared, based on a literature 
review, and circulated first among the authors and then 
to all ICOCS members and iterative edits were incorpo-
rated. In sum, we have selected those recent therapeu-
tic advances judged by a range of experts to be of most 
relevance to the treatment of OCD, including products 
that are not licensed or labelled for treatment of OCD by 
the US Food and Drug Administration (FDA) (Table 1), 
which are marked with an asterisk (*) throughout the 
article, based on new and emerging evidence from clini-
cal and translational science
Global assessment of obsessive-compulsive 
disorder
A comprehensive assessment of OCD requires trained 
clinicians who perform direct interviews with the patient 
and, whenever possible, with family members, so that 
an accurate diagnosis can be determined and individu-
alized treatment can be tailored. The hallmarks of OCD 
are obsessions (recurrent, intrusive, unwanted thoughts, 
images or impulses and compulsions (repititive behav-
iours or mental acts that the individual feels compelled 
to perform), these can present together or separately.
The most common symptom dimensions of OCD are 
contamination/washing, aggression/checking, symmetry/
ordering/arranging, sexual/religious (also known as ‘taboo 
thoughts’) and hoarding (Rosario-Campos et al., 2006). 
Importantly, according to DSM-5, a diagnosis of Hoarding 
Disorder should be assigned when symptoms pertain to 
this single dimension (American Psychiatric Association, 
2013). The presence and severity of symptoms can be 
measured by validated instruments (Goodman et al., 
1989; Rosario-Campos et al., 2006; Storch et al., 2010), 
which is relevant to tailoring the behavioural treatment 
and monitoring treatment response objectively. For the 
OCD diagnosis, while free-form interviews by clinicians 
are commonly used, structured interviews offer advan-
tages in terms of objectivity and psychometric properties 
(Rapp et al., 2016). Suitable interviews for the diagnosis 
of OCD in adulthood include the Structured Clinical 
Interview for DSM-5 Disorders (First et al., 2016), or the 
Mini International Neuropsychiatric Interview (Sheehan 
et al., 1998). The Yale–Brown Obsessive-Compulsive 
Scale (Y-BOCS) is the gold-standard for assessing symp-
tom severity in diagnosed adult patients, and incorporates 
a detailed checklist for individual symptoms (Goodman 
et al., 1989). For initial screening, six brief questions can 
be used. These include as follows: (1) Do you wash or 
clean a lot? (2) Do you check things a lot? (3) Is there any 
thought that keeps bothering you that you would like to 
get rid of but can’t? (4) Do your daily activities take a long 
time to finish? (5) Are you concerned about orderliness or 
symmetry? (6) Do these problems trouble you? Positive 
response to one or more statements would indicate a 
need for more detailed assessment (Fineberg et al., 2008).
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Obsessions and compulsions tend to occur concomitantly 
in the vast majority of people with OCD (Shavitt et al., 
2014). In addition, compulsions are commonly preceded 
not only by obsessions but also by subjective experi-
ences of incompleteness, or ‘not feeling just-right’, or 
so-called sensory phenomena (perceptual experiences 
that precede or accompany compulsions) (Shavitt et al., 
2014). We could expect these phenomena to be targeted 
by cognitive-behavioural techniques in a way similar to 
the premonitory urges in the behavioural treatment of tic 
disorders (McGuire et al., 2015).
Another relevant clinical feature that merits attention 
when assessing subjects with OCD is the degree of 
insight, meaning the extent to which the person recog-
nizes that his/her beliefs are not true (Eisen et al., 1998). 
Insight (good or fair insight, poor insight, absent insight/
delusional beliefs) is a diagnostic specifier for OCD, body 
dysmorphic disorder (BDD) and hoarding disorder in 
the DSM-5 (American Psychiatric Association, 2013). In 
general, subjects with OCD have at least good insight, 
with only a minority presenting poor insight or delusional 
OCD (Shavitt et al., 2014). The presence of tic symptom-
atology represents another clinically relevant diagnostic 
specifier in the DSM-5, as tic may predict a more favour-
able response to dopamine antagonist agents (Bloch et 
al., 2006). Finally, the clinician must obtain information 
regarding avoidance behaviours, which commonly occurs 
as a means to handle the distress evoked by the obses-
sions and constitutes one of the main targets of the cogni-
tive-behavioural treatment for this disorder (Drummond, 
2014). Functional impairment varies in OCD. It is an 
important domain that reflects clinical severity and con-
stitutes an indirect measure of improvement during treat-
ment. Impairment can be measured indirectly with OCD 
severity scales or with specific measures [e.g., the WHO 
Disability Assessment Schedule 2.0 (Üstün et al., 2010) or 
the Cognitive Assessment Instrument of Obsessions and 
Compulsions (Dittrich et al., 2011)].
Comorbidity is almost always present with OCD and 
is often ‘phase-specific’ (Pallanti and Grassi, 2014). 
Assessment of specific comorbidities, like tic disorders, 
anxiety and depressive disorders, disruptive disorders, eat-
ing disorders, autism spectrum disorder (ASD), attention 
deficit hyperactivity disorder (ADHD) and schizophrenia 
(Zohar, 1997), is essential in guiding the formulation of an 
effective treatment strategy. Comorbidity has also been a 
focus of emerging genetic studies of OCD. For example, a 
recent study in 4645 OCD patients found different geno-
types to be associated with different OCD comorbidities. 
Thus, OCD comorbid with bipolar disorders was associ-
ated with COMT, OPRM1 and GRIK1 genotypes; OCD 
and depressive disorders were associated with OPRM1 
and CYP3A4/5 genotypes; OCD comorbid with ADD/
ADHD was associated with 5HT2C genotypes; and OCD 
Table 1 The US Food and Drug Administration status of treatments covered in this article
Treatment
FDA status for treatment of OCD
Adults Children and adolescents
Serotonin reuptake inhibitors
 Clomipramine Approved Approved from 10 years of age
 Fluoxetine Approved Approved from 8 years of age
 Fluvoxamine Approved Approved from 8 years of age
 Sertraline Approved Approved from 6 years of age
 Paroxetine Approved Not approved
 Citalopram Not approved
 Escitalopram Not approved
Second-generation antipsychotics
 Risperidone Not approved
 Aripiprazole Not approved
 Quetiapine Not approved
Novel pharmacotherapies
 Glutamate modulators (memantine, riluzole, topiramate, lamotrigine, N-Acetylcysteine, Ketamine) Not approved
 d-amphetamine Not approved
 Morphine Not approved
 Pindolol Not approved
 Clonazepam Not approved
 Buspirone Not approved
 Lithium Not approved
 Ondansetron Not approved
Noninvasive brain stimulation
 Low-frequency r-TMS at supplementary motor area Not approved
 Low-frequency r-TMS at orbitofrontal cortex Not approved
 High-frequency-deep rTMS over the dorsomedial prefrontal cortex/anterior cingulate cortex Approved for treatment of resistant OCD
 Transcranial direct current stimulation Not approved
 Electroconvulsive therapy Not approved
Invasive procedures
 Deep brain stimulation Humanitarian device exemption for severe refractory 
OCD
 Stereotactic neurosurgical procedures Not approved
FDA, the US Food and Drug Administration; OCD, obsessive-compulsive disorder; r-TMS, recurrent-transcranial magnetic stimulation.
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comorbid with anxiety was associated with CYP3A4/5 
genotypes (Nezgovorova et al., 2018). However, these 
findings should be viewed with caution, as the ‘candi-
date gene’ approach, in which specific genes are tested 
for association with specific disorders, chosen for the bio-
logical plausibility of their relationship, using relatively 
small samples of affected subjects and healthy controls, 
has been criticized for overestimating statistical associ-
ations. Attempts to replicate the findings have tended 
to produce disappointing results. Therefore, more unbi-
ased forms of the association study, such as genome-wide 
association studies (GWAS), which test the association 
between a disease and multiple genetic variants across 
the whole genome, are to be preferred (Gordon, 2018; 
National Advisory Mental Health Council Workgroup 
on Genomics, 2019). A recent meta-analysis of GWAS of 
eight psychiatric disorders identified a common genetic 
factor linking OCD, anorexia nervosa and Tourette’s syn-
drome (Lee et al., 2019b).
Interestingly, comorbid disorders that start before the 
onset of OCD symptoms seem to influence the occur-
rence of additional comorbidities over time. In a cohort 
of 1001 patients with OCD, separation anxiety disorder 
preceded OCD in 17.5% of individuals and was associ-
ated with a higher lifetime frequency of posttraumatic 
stress disorder; ADHD preceded OCD in 5.0% of sub-
jects, and was associated with higher lifetime frequen-
cies of substance abuse and dependence; tic disorders 
preceded OCD in 4.4% of subjects and were associated 
with higher lifetime frequencies of OCD spectrum disor-
ders (de Mathis et al., 2013). In children and adolescents, 
in addition to the considerations for the adult subjects, a 
history of paediatric autoimmune neuropsychiatric disor-
ders associated with streptococcal infections (PANDAS) 
should be taken, as this could also have treatment impli-
cations (Wilbur et al., 2019). Taken together, these find-
ings emphasize the importance of identifying comorbid 
disorders, as they may serve as markers of different bio-
logical or clinical substrates of potential relevance for 
treatment planning (see section Future directions for 
research).
OCD needs to be differentiated from: anxiety disorders 
presenting with recurrent fears (as in the phobias) and 
excessive worry (as in generalized anxiety disorder); 
ruminations accompanying depressive mood in depres-
sive disorders; OCD-related disorders like BDD (where 
there are specific concerns with one’s appearance), 
hair-pulling disorder (the only compulsion); tic disorders; 
eating disorders (concerns focussed on weight and shape 
and food); psychotic disorders (especially in poor-insight 
OCD and so-called schizo-obsessive disorder) and obses-
sive-compulsive personality disorder (with the hallmarks 
of enduring rigidity and perfectionism over the lifetime) 
(American Psychiatric Association, 2013).
Along with the identification of the most bothersome 
symptoms, the clinician should investigate the age of 
onset of symptoms and the age when a diagnosis of OCD 
has been determined, because these data can help to pre-
dict the prognosis (Fineberg et al., 2019). OCD frequently 
emerges in childhood, in which group accurate diagnosis 
is essential for care planning. Paediatric clinicians can 
ask simple screening questions such as ‘do you ever have 
unwanted thoughts or worries that won’t go away? Are 
there things you have to do over and over again, even 
though you don’t want to or that don’t make sense?’ The 
formal diagnosis should be made with a structured inter-
view and the nationwide translated versions of the stand-
ardized Children’s Y-BOCS (CY-BOCS), which has good 
reliability (López-Pina et al., 2015a,b).
Awareness of other conditions associated with the onset 
and course of OCD symptoms can also be of help in 
treatment planning, because OCD frequently follows 
a chronic course, with most patients reporting resid-
ual symptoms, or present an episodic course with long 
symptom-free periods (Skoog and Skoog, 1999). For 
example, a cross-cultural study has shown an associa-
tion between reproductive cycle events and the onset 
(mostly menarche) or exacerbation of OCD during the 
premenstruum, pregnancy, postpartum and menopause 
(Guglielmi et al., 2014). Relevant to prevention strategies, 
exacerbation during or after first pregnancy posed a sig-
nificant risk to exacerbation in or after a subsequent preg-
nancy. The underlying factors responsible for triggering 
exacerbation remain to be understood, especially the role 
of oestrogen and oxytocin (Guglielmi et al., 2014).
Information on the family history of OCD, tics and other 
psychiatric disorders and the understanding of OCD 
among family members and family accommodation 
are also relevant to treatment-planning and adherence. 
Evidence shows that successful treatment depends on 
the reduction of the participation of the family members 
in the patient’s compulsive behaviours (i.e., reduction of 
accommodation) (Gomes et al., 2017). Moreover, a recent 
analysis suggested that children with a family history of 
OCD have a six times lower response to CBT (Garcia et 
al., 2010).
Suicidality should be included when assessing people 
with OCD (Dell’Osso et al., 2018). A recent meta-analysis 
(Angelakis et al., 2015) found that OCD patients showed 
relatively increased risk of ‘suicidality’, when compared 
with healthy controls. In terms of absolute risk, estimates 
vary. Among 582 patients with OCD, 36% reported life-
time suicidal thoughts, 20% had made suicidal plans, 11% 
had already attempted suicide and 10% presented with 
current suicidal thoughts (Torres et al., 2011). In another 
study of 425 outpatients, recruited by the ICOCS net-
work, 14.6% of the sample reported at least one suicide 
attempt during their lifetime (Dell’Osso et al., 2018). In 
the study by Torres et al. (2011), comorbid depressive 
disorder and posttraumatic stress disorder were asso-
ciated with a range of suicidal behaviours. Sexual/reli-
gious symptoms and comorbid substance use disorders 
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were associated with suicidal thoughts and plans, while 
impulse control disorders were associated with current 
suicidal thoughts, suicide plans and attempts. In the 
study of Dell’Osso et al. (2018), comorbid tic disorders as 
well as medical disorders and a previous history of hospi-
talization were also associated with increased suicidality.
Neuropsychological assessment of patients with OCD 
suggests that there are deficits across a broad range of 
domains (Fineberg et al., 2018a). For example, a recent 
meta-analysis found that patients with symptoms related 
to symmetry and orderliness were more likely to have 
poor performance on memory, visuospatial ability, ver-
bal working memory and cognitive flexibility tests, 
whereas patients with doubting and checking were more 
likely to perform poorly on memory and verbal memory 
tasks (Bragdon et al., 2018). Other meta-analyses have 
found cognitive flexibility and response inhibition to be 
impaired in OCD in general (all literature pooled), with 
medium–large effect sizes (Lipszyc and Schachar, 2010; 
Chamberlain et al., 2019). It must be considered that 
comorbid neurodevelopmental disorders, such as ASD 
(Postorino et al., 2017), or ADHD are expected to influ-
ence performance on distinct tests, especially but not 
exclusively in youth.
Behavioural analysis of OCD involves obtaining a history 
to ascertain the specific situations that provoke obsessions, 
anxious thoughts or uncomfortable feelings and then 
separating out the compulsions or anxiolytic behaviours. 
This is important, as during therapy the patient needs to 
face up to the anxiety-provoking thoughts or uncomfort-
able feelings while resisting the urge to ‘put this right’ 
using compulsive thoughts, behaviours or avoidance. Full 
descriptions of behavioural analysis are given elsewhere 
(Drummond, 2014). From a cognitive perspective, there 
have been several theories about the underlying beliefs 
that may trigger OCD, such as the failure to challenge 
underlying beliefs sufficiently (Emmelkamp et al., 1988), 
inflated responsibility and guilt if compulsions were 
not acted upon and negative consequences occurred 
(Salkovskis, 1985, 1999), or an overinflated idea of danger 
(Jones and Menzies, 1998) (see section Novel forms of 
psychotherapy below).
Early intervention in obsessive-compulsive 
disorder
OCD frequently has an onset early in life (Fineberg et al., 
2019). Childhood or adolescent onset accounted for more 
than 50% of the sample in a recent international multisite 
report (Dell’Osso et al., 2016). Unfortunately, early onset 
is all too often not associated with early help-seeking 
and recognition of the illness. OCD has been consist-
ently associated with a long duration of untreated illness 
(DUI) – around 7 years on average (Dell’Osso et al., 2019) 
– with this period accounting, in many cases, for more 
than half of the overall duration of illness (Albert et al., 
2019; Dell’Osso et al., 2019). Longer DUI implies late 
interventions and poor therapy response, particularly in 
relation to pharmacological treatment (Dell’Osso et al., 
2010; Albert et al., 2019). The need for service investment 
in early intervention for OCD is further highlighted by 
studies indicating that OCD is among the top 10 most 
disabling of all disorders, accounting for 2.2% of all 
years lost to disability (Ayuso-Mateos, 2006), with eco-
nomic costs to society including those associated with 
lost productivity, which are long-lasting and profound. 
It has been estimated that in the USA, over $10 billion 
dollars per year are spent on treatments for OCD alone 
(Hollander et al., 2016).
OCD has been traditionally viewed as a secretive illness 
with some phenotypes (e.g., with sexual, religious or 
aggressive content) being particularly associated with 
reluctance to seek help (Dell’Osso et al., 2015). There 
may also be difficulty detecting the disorder in childhood 
(Storch et al., 2014). Nonetheless, a greater effort needs to 
be made at multiple levels (e.g., education, service devel-
opment and screening of ‘at risk’ individuals) to imple-
ment effective strategies for prevention, early diagnosis 
and intervention. For instance, there have been reports 
indicating that the earliest symptoms shown by OCD 
patients belong to the symmetry and ordering dimension 
(Kichuk et al., 2013) and these may represent a red flag 
for early detection of subthreshold/early symptoms.
Children of individuals with OCD represent another 
high-risk group deserving attention and potentially 
needing preventive interventions. The presence of tic, 
paediatric acute-onset neuropsychiatric syndrome, obses-
sive-compulsive personality disorder and impulse control 
disorders may be indicators of comorbid OCD or herald 
the subsequent development of OCD (Fineberg et al., 
2019). Staging models may also be useful (Fineberg et 
al., 2019; Fontenelle and Yücel, 2019), with four major 
stages proposed (from stage 0 ‘increased risk, asympto-
matic’ to stage 4 ‘severe illness’). However, their clini-
cal utility and applicability remain to be investigated. 
Interventions such as psychoeducation and reduction of 
family accommodation represent promising areas for pre-
vention and early intervention when OCD is at its early 
stages in high-risk groups (Brakoulias et al., 2018). One 
Australian health service (Brakoulias, 2018) has recently 
begun using existing early intervention services for 
psychosis to provide early intervention to patients with 
OCD (Brakoulias, 2018) (Western Sydney Obsessive-
Compulsive and Related Disorders Service).
Cognitive behavioural therapy, selective 
serotonin reuptake inhibitor or their 
combination as a first-line treatment for 
adults with obsessive-compulsive disorder
Pharmacological therapies (SSRIs and the tricyclic clo-
mipramine) (Zohar et al., 1996; Fineberg et al., 2012) and 
psychological therapies (ERP, CBT) (Abramowitz, 2006) 
are often efficacious in treating OCD in adults. As SSRIs 
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and CBT have been thought to have broadly similar effi-
cacy in acute treatment, current guidelines recommend 
taking account of patients’ clinical features, needs and 
preference as well as service availability when choosing 
a first-line treatment (Baldwin et al., 2014). Monotherapy 
with CBT involving ERP is particularly recommended 
as an initial treatment in those with mild–to-moderate 
OCD, in the absence of severe depression, in those who 
do not prefer medications and where this form of treat-
ment is accessible, available and preferred by patients 
(National Institute for Health and Clinical Excellence, 
2005a; Koran et al., 2007; Katzman et al., 2014; Janardhan 
Reddy et al., 2017). In contrast, SSRIs are particularly 
recommended as a first-line treatment option in more 
severe OCD, in those who have comorbid depression, in 
those with previous history of good response to SSRIs, in 
those who are uncooperative with CBT or in situations 
where ERP/CBT is not available, accessible or preferred 
by patients. A combination of CBT involving ERP and 
SSRIs is often recommended in severe OCD, in the pres-
ence comorbid depression and in poor responders to CBT 
or SSRIs alone (National Institute for Health and Clinical 
Excellence, 2005b; Skapinakis et al., 2016b; Hirschtritt et 
al., 2017; Janardhan Reddy et al., 2017). In essence, most 
guidelines recognize SSRIs and CBT involving ERP as 
first-line monotherapies, but prefer CBT involving ERP 
over SSRIs.
Several meta-analyses and systematic reviews have 
demonstrated SSRIs and clomipramine (Ackerman and 
Greenland, 2002; Soomro et al., 2008; Skapinakis et al., 
2016b) and CBT involving ERP to be more effective 
than placebo (frequently waiting list in CBT trials) in 
the treatment of OCD (Gava et al., 2007; Rosa-Alcázar 
et al., 2008). Although an earlier meta-analysis suggested 
superiority of clomipramine over SSRIs (Ackerman and 
Greenland, 2002), a recent network meta-analysis failed 
to demonstrate the superiority of clomipramine over 
SSRIs (Skapinakis et al., 2016b). Direct head-to-head 
comparisons of various medications are few and there 
seems to be no individual differences in efficacy among 
SSRIs (Skapinakis et al., 2016b), although, of course, they 
may differ in side effect profiles.
Most studies of CBT involving ERP included sympto-
matic patients stabilized on antidepressants (Skapinakis 
et al., 2016b). Although the observed effect size of CBT 
was larger than the SSRIs and clomipramine, this supe-
riority could well be attributed to the additive or syn-
ergistic effects of two effective treatment modalities. 
Therefore, it is not clear whether the efficacy data attrib-
uted to CBT with ERP can be generalized to patients 
who are not taking medication for OCD. The efficacy 
of CBT as monotherapy still needs to be established 
clearly in drug-naïve or drug-free patient population 
for it to be recommended as initial monotherapy in this 
population.
Some studies suggest that a combination of CBT and an 
SSRI may be superior to SSRI monotherapy (Foa et al., 
2005; Liu et al., 2005; Franklin et al., 2011; Romanelli et al., 
2014; Meng et al., 2019), exposure monotherapy (Cottraux 
et al., 1990, Fineberg et al., 2018a) or multimodal CBT 
(Hohagen et al., 1998). However, it is uncertain whether 
combining ab-initio CBT and an SSRI is advantageous 
compared to either treatment used alone (Albert et al., 
2012). Confidence in the superiority of the combination 
of medications and psychotherapy partly stems from the 
fact that, as described above, most psychotherapy trials 
are considered variants of combination trials because 
most patients in these studies were stabilized on SSRI or 
clomipramine (Skapinakis et al., 2016b). Most guidelines 
and literature recommend a combination of SSRIs and 
CBT involving ERP in severe OCD, but the recommen-
dation is based on evidence of its efficacy as an augment-
ing strategy in patients who have clinically significant 
symptoms despite treatment with medications and not 
necessarily in severe OCD (Simpson et al., 2008, 2013). 
A recent randomized feasibility study that included 
patients treated in primary care found that although com-
bined treatment with SSRI and ERP was associated with 
the largest improvement after 16 weeks, SSRI monother-
apy was the most efficacious and cost effective treatment 
after 52 weeks (Fineberg et al., 2018b). If replicated, this 
finding would carry major implications for health services 
planning, especially where resources are limited, such as 
lower and middle income countries.
The critical importance of adequate 
treatment of obsessive-compulsive disorder 
in children and young people
For children and young people, CBT should always be the 
first-line approach (Sánchez-Meca et al., 2014; Skapinakis 
et al., 2016a), with ERP as core elements (Lewin et al., 
2014). ERP is both highly effective and also an accept-
able intervention for youth ages 3–8  years with OCD 
(Lewin et al., 2014). Children with a strong family history 
of OCD are reported to respond less well to conventional 
CBT (Garcia et al., 2010), possibly owing to family accom-
modation of their symptoms. Key adaptations for younger 
children include extensive parental involvement target-
ing family accommodation and frequent family meetings 
while delivering a full course of ERP. According to the 
study of Sánchez-Meca et al. (2014), effect sizes were 
large for CBT (d+  =  1.742) and combined (medication 
plus CBT) interventions (d+ = 1.710) and moderate for 
pharmacological only treatments (d+  =  0.746). Family-
based CBT (Piacentini et al., 2011; Freeman et al., 2014) 
is also effective for children and adolescents with OCD, 
especially when there is a high degree of accommodation. 
The extant literature also supports CBT when delivered 
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in group settings. More recently, the use of technical 
devices (smart phones and tablets) using App-delivered 
CBT seems promising.
Medication is, however, indicated for children and 
young people when symptoms are more severe, CBT 
has failed, skilled CBT is unavailable, and there is a 
comorbid disorder (e.g., depression) that may respond 
to medication, or when, in the judgement of the par-
ent or clinician, earlier introduction of medicines is 
clinically indicated. SSRIs have been shown in rand-
omized controlled trials to be well tolerated and effec-
tive in youth (Geller et al., 2004; Skarphedinsson et al., 
2015). Sertraline and fluvoxamine have been approved 
for children from 6 to 8 years of age. Dosing schedules 
should include low starting doses, slow titration sched-
ules and maximum recommended doses. Following 
adequate response and stabilization, treatment should 
be reviewed after 6–12 months.
In the case of nonresponse or inadequate response, 
another SSRI should be tried (Geller et al., 2004, 2012; 
Locher et al., 2017). Treatment with SSRIS in CBT-
resistant patients may improve OCD symptoms. Although 
clomipramine may be effective, it is not recommended as 
a first-line treatment because of its potential side effects. 
However, if there are no cardiac contraindications, clomi-
pramine* is also an option in youth but requires electro-
cardiogram monitoring. In the case of insufficient efficacy 
of drug treatment with several SSRIs and clomipramine, 
or in the presence of tic disorder, augmentation with 
antipsychotics, for example, aripiprazole* or risperidone* 
in low dosage may be used. Minimal duration on antipsy-
chotics (these medications are not approved or indicated 
for paediatric use) is encouraged and close monitoring is 
required.
Relapse prevention
Relapse prevention strategies play an essential role for 
the optimal clinical management of OCD, consider-
ing its frequently chronic course and relapsing nature. 
Recovery occurs in only about one-fifth of adult cases, 
while for children, the mean persistence rates for full or 
subthreshold OCD have been estimated at around 60% 
(Maina et al., 2001; Stewart et al., 2004). Earlier age of 
OCD onset, increased illness duration, inpatient status, 
the presence of comorbidities and a positive family his-
tory seem to predict greater rates of persistence (Geller 
et al., 2003; Stewart et al., 2004). Furthermore, relapses 
in OCD are associated not only with considerable dis-
tress, significant functional impairment and impairment 
of quality of life (Hollander et al., 2010) but also with a 
decreased response to a previous efficacious treatment 
(Maina et al., 2001).
To date, relapse prevention studies in OCD have mainly 
investigated SSRIs and clomipramine as the maintenance 
treatment, with the duration of treatment under place-
bo-controlled conditions extending up to 12  months. 
Studies with a longer follow-up period or investigating 
relapse following CBT are relatively scarce. In the case 
of adults, the majority of relapse prevention studies have 
shown an overall superiority of SSRI compared with pla-
cebo in preventing relapse (Fineberg et al., 2007) and that 
discontinuation of maintenance treatment, even after a 
period of prolonged well-being under SSRI, is associated 
with a heightened relapse risk. Relapse was particularly 
prominent in patients with comorbidities, which is the 
rule rather than the exception in children with OCD. 
As childhood and adolescence are critical periods for 
achievement of social, educational and occupational mile-
stones, relapse prevention is particularly relevant for the 
younger patient population (Fineberg et al., 2019). There 
has been one randomized controlled relapse prevention 
study in paediatric OCD, which showed an advantage for 
paroxetine* over placebo (Geller et al., 2004). As there is 
no available evidence suggesting a duration of treatment 
beyond which treatment can be discontinued safely, 
more recent guidelines emphasized the importance of 
maintaining medication for at least 12 months to reduce 
relapse risk (Baldwin et al., 2014).
The clinician’s role in enabling an informed choice about 
whether or not to discontinue medication at any par-
ticular time is challenging, considering the limitations 
of the available relapse prevention studies. Strategies 
for safely managing emerging relapse, such as reinstat-
ing either ‘booster’ CBT or medication at the first sign of 
symptoms, do not have established evidence of efficacy. 
Nevertheless, it is advisable to establish a relapse-man-
agement plan, in cooperation with patients and their fam-
ilies based on vigilance for emergent symptoms and rapid 
access to treatment previously known to be effective. If 
medication is to be discontinued, this should be done 
gradually, after a careful explanation of the potential con-
sequences, such as withdrawal symptoms and relapse 
risk. SSRI tapering over a period of months, rather than 
weeks, may reduce the risk of withdrawal symptoms 
(Horowitz and Taylor, 2019).
Treatment-resistant obsessive-compulsive 
disorder – novel pharmacotherapies tested in 
adults
After well supported first- and second-line treatments 
and strategies have been exhausted, some patients will 
continue to experience impairing OCD symptoms. Next-
step treatment strategies may include continuing with 
the chosen SRI for an extended period of time, switching 
to another SRI, augmenting the SRI with a second-gen-
eration antipsychotic agent* or raising the dose of SRI to 
the highest tolerated level* (Fineberg and Craig, 2007; 
Bandelow et al., 2008; Fineberg et al., 2012; Stein et al., 
2012).
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Although switching to another SRI often is recommended, 
there is little evidence to support this approach in OCD. 
When a partial or moderate response has been achieved 
following the adequate first-line treatment, there is 
randomized controlled trial (RCT) and meta-analytic 
evidence to support augmentation with an second-gener-
ation antipsychotic (Brakoulias and Stockings, 2019; Dold 
et al., 2015; Stein et al., 2012; Zhou et al., 2019); however, 
the use of these agents would be considered off-label. Of 
these agents, risperidone* is supported by the greatest 
number of studies, which have generally been positive 
(Brakoulias and Stockings, 2019). Two RCTs (Muscatello 
et al., 2011; Sayyah et al., 2012), several open-label studies 
(Connor et al., 2005; Pessina et al., 2009; Ak et al., 2011), 
and multiple case reports have demonstrated the effi-
cacy in OCD of aripiprazole* as an augmentation agent 
(Matsunaga et al., 2011; Higuma et al., 2012; Hou and Lai, 
2014; Ercan et al., 2015; Akça and Yilmaz, 2016; Patra, 
2016; Brakoulias and Stockings, 2019). One meta-anal-
ysis also found a larger effect size for aripiprazole than 
for risperidone: Cohen’s d  =  1.11 (aripiprazole) versus 
d = 0.53 (risperidone) (Veale et al., 2014). Quetiapine* has 
also been examined as an augmentation agent in OCD, 
but the evidence is conflicting. Despite several positive 
studies (Atmaca et al., 2002; Denys et al., 2004; Vulink et 
al., 2010; Diniz et al., 2011), negative results have been 
found in many placebo-controlled trials (Carey et al., 
2005; Kordon et al., 2008; Fineberg et al., 2013).
Contrary to the depression literature, a meta-analysis of 
SSRIs in OCD found that high doses (high end of rec-
ommended dosage, not higher than recommended doses) 
were more effective than medium or low doses in the 
first-line treatment of OCD (Bloch et al., 2010). Response 
was more robust for patients with comorbid tics and 
in individuals who had received more than 12  weeks 
of maximal SSRI monotherapy (Bloch et al., 2008). 
However, tolerability is a significant issue as compared 
with lower doses so that this strategy requires caution in 
primary care settings (Stein et al., 2012). The Food and 
Drug Administration in the USA raised a safety warning 
in 2011 against citalopram doses higher than 40 mg/day 
due to a modest but probable risk of arrhythmias (US 
Food and Drug Administration, 2012). However, a more 
recent meta-analysis identified only 18 cases where elec-
trocardiogram QTc prolongation or torsades de pointes 
was associated with citalopram at doses between 20 and 
60  mg/day. The authors concluded that these cardiac 
adverse events were infrequent (Tampi et al., 2015).
When an inadequate treatment response persists, less 
well supported treatment strategies (lacking multiple 
randomized, controlled trials or meta-analyses) may be 
considered (Koran et al., 2007; Koran and Simpson, 2013), 
including use of glutamate modulators*, d-ampheta-
mine* or oral morphine sulfate*.
Glutamate modulators such as memantine*, riluzole*, 
topiramate*, lamotrigine*, N-acetylcysteine* and ket-
amine* have varying levels of support (Koran et al., 
2007; Pittenger et al., 2011; Koran and Simpson, 2013; 
Pittenger, 2015). Memantine augmentation showed ben-
efit in case studies and open-label trials (Poyurovsky et 
al., 2005; Pasquini and Biondi, 2006; Aboujaoude et al., 
2009; Feusner et al., 2009; Stewart et al., 2010; Bakhla et 
al., 2013). In addition, two RCTs of memantine showed 
exceptionally high response rates (100% in one study), 
inconsistent with the literature (Ghaleiha et al., 2013; 
Haghighi et al., 2013). Riluzole augmentation showed 
promise in a case series and open-label trial (Coric et al., 
2003, 2005). Subsequent small controlled studies have 
been mixed (Pittenger et al., 2008; Emamzadehfard et 
al., 2016). While topiramate augmentation showed prom-
ise in case studies and open-label trials (Rubio et al., 
2006; Van Ameringen et al., 2006; Van Ameringen and 
Patterson, 2015), small RCTs have also produced mixed 
results (Mowla et al., 2010; Berlin et al., 2011; Afshar et al., 
2014). Lamotrigine augmentation showed mixed results 
in case reports (Kumar and Khanna, 2000; Uzun, 2010; 
Arrojo-Romero et al., 2013; Hussain et al., 2015) and ben-
efits in two small RCTs (Bruno et al., 2012; Khalkhali et 
al., 2016). Limited data suggest that N-acetylcysteine 
is of benefit in some cases of refractory OCD (Lafleur 
et al., 2006), with mixed data in four RCTs (Afshar et al., 
2012; Sarris et al., 2015; Paydary et al., 2016; Costa et al., 
2017). N-acetylcysteine is generally well tolerated. A 
single intravenous dose of ketamine has been reported 
to be of rapid (in hours) and robust benefit in unmed-
icated adults with OCD in case report and open-label 
studies (Rodriguez et al., 2011, 2016) and a randomized 
controlled cross-over study (Rodriguez et al., 2013). In an 
open-label trial of medicated OCD adults with multiple 
comorbidities, depression improved on ketamine but 
improvement in OCD symptoms was minimal, and two 
patients developed new-onset irritability and suicidal 
ideation (Bloch et al., 2012; Niciu et al., 2013). Experience 
with intranasal ketamine in OCD is very limited (Adams 
et al., 2017; Rodriguez et al., 2017). Ketamine should only 
be administered at sites with expertise in this approach, 
with appropriate precautions including monitoring for 
side effects and screening individuals who have a current 
or past substance abuse problem (Sanacora et al., 2017).
In two double-blind, placebo-controlled studies, d-am-
phetamine was superior to placebo in unmedicated 
OCD adults (Insel et al., 1983; Joffe et al., 1991). A sub-
sequent double-blind comparison of SSRI augmentation 
with d-amphetamine versus high-dose caffeine showed 
benefit of both drugs (Koran et al., 2009). Oral morphine 
showed benefit in a case series (Warneke, 1997) and in 
a double-blind crossover study (Koran et al., 2005) in 
adults with OCD. Precautions should be taken in the 
case of both d-amphetamine and morphine to screen out 
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individuals who have current or past substance abuse 
(Koran et al., 2007).
Other drugs, such as pindolol*, clonazepam*, buspirone*, 
or lithium*, have been tested, but the results have been 
mixed and some of the placebo-controlled trials have not 
found positive results. Some promising results have been 
found with the 5HT3 antagonist ondansetron* (Serata 
et al., 2015) and a clinical trial is currently underway 
(ClinicalTrials.gov, 2017) though a double-blind place-
bo-controlled trial of low daily dosages of odansetron* 
(0.5 and 0.75 mg) in a relatively large sample was nega-
tive (ClinicalTrials.gov, 2015).
Treatment-resistant obsessive-compulsive 
disorder – noninvasive neurostimulation
Noninvasive neuromodulatory interventions targeting 
the corticostriatothalamocortical (CSTC) circuits hold 
promise as augmenting intervention for treatment-re-
sistant OCD (Lusicic et al., 2018). Repetitive transcra-
nial magnetic stimulation (rTMS)* is the best studied 
noninvasive modulatory intervention in OCD. rTMS 
delivered at low-frequency rTMS (≤1  Hz) (LF-rTMS) 
is thought to inhibit the activity of underlying cortical 
regions, while high-frequency rTMS, provided at ≥5 Hz, 
is thought to enhance cortical activity (Lefaucheur et al., 
2014). Conventional rTMS, provided through the fig-
ure-8 coil, is relatively focal, modulating superficial cor-
tical regions over a depth of around 2 cm (Lefaucheur 
et al., 2014). LF-rTMS* protocols targeting the sup-
plementary motor area (SMA) have been found to be 
helpful for OCD in multiple RCTs and meta-analyses 
(Mantovani et al., 2010; Gomes et al., 2012; Hawken et al., 
2016; Zhou et al., 2017; Rehn et al., 2018). This effect has 
been found to last up to 3 months (Gomes et al., 2012). A 
recent trial demonstrated superior efficacy of this proto-
col over antipsychotic augmentation in treatment-resist-
ant OCD subjects (Pallanti et al., 2016). However, given 
recent inconsistent reports on inhibitory rTMS proto-
cols targeting the SMA (Arumugham et al., 2018; Harika-
Germaneau et al., 2019; Pelissolo et al., 2016), there is a 
need for large multicentre trials to confirm its efficacy at 
this location.
LF-rTMS targeting the orbitofrontal cortex (OFC)* has 
also shown promise in small RCTs (Ruffini et al., 2009; 
Nauczyciel et al., 2014). There is a need for larger trials 
targeting the OFC to confirm its efficacy and tolerability. 
RCTs targeting the dorsolateral prefrontal cortex have, 
in contrast – and unlike in major depressive disorder – 
shown highly inconsistent findings in OCD (Lusicic et 
al., 2018). A multisite randomized sham-controlled trial 
found high-frequency deep rTMS, using an H7 coil, over 
the dorsomedial prefrontal cortex/anterior cingulate cor-
tex to be efficacious and well tolerated in a treatment 
resistant OCD population (Carmi et al., 2019). This FDA 
approval and CE (Conformité Européene) certification 
device for the treatment of resistant OCD. However, 
considering the cost of this device, there is a need for 
replication studies confirming the efficacy of the above 
protocol, which included personalized symptom provo-
cation as an interventional component. Less-expensive 
deep coils, which have shown promise in targeting the 
dorsomedial prefrontal cortex in open-label trials on 
OCD (Modirrousta et al., 2015; Dunlop et al., 2016), are 
yet to be evaluated under controlled conditions.
Transcranial direct current stimulation (tDCS)* involves 
administration of low-amplitude (1–2  mA) electric cur-
rent to the brain between a cathode and anode. Anodal 
tDCS is thought to enhance cortical excitability and 
cathodal tDCS to have an inhibitory effect (Rachid, 
2019). The SMA and OFC are key targets. A randomized 
sham-controlled trial (n  =  24 treatment-resistant OCD 
subjects) demonstrated efficacy for anodal tDCS admin-
istered over bilateral pre-SMA and cathodal tDCS over 
right supraorbital regions (Gowda et al., 2019). However, 
another randomized crossover trial (n  =  12) found clin-
ical improvement with cathodal tDCS over pre-SMA, 
while anodal tDCS was ineffective (D’urso et al., 2016). 
Thus, replication studies are needed to determine the 
optimal stimulation protocol for tDCS over SMA in 
OCD*. Another randomized sham-controlled trial (n = 21 
treatment-resistant OCD patients) showed efficacy for 
cathodal tDCS delivered over the OFC and the anode 
over the right cerebellum, but the effect was not sus-
tained at follow-up (Bation et al., 2019). Other promising 
results in treatment-resistant OCD for protocols target-
ing OFC and other cortical regions, such as dorsolateral 
prefrontal cortex and dorsomedial prefrontal cortex, are 
found in case reports and small uncontrolled studies and 
have to be confirmed in well designed trials (Brunelin 
et al., 2018; Rachid, 2019). Furthermore, studies present 
significant heterogeneity and methodological differences 
in sample selection criteria, concomitant treatment and 
tDCS stimulation protocols (da Silva et al., 2019; Rachid, 
2019). Some authors suggest that overall cathodal tDCS 
may be better than anodal in treating OCD (Rapinesi et 
al., 2019).
Currently, there are no RCTs to support the efficacy of 
electroconvulsive therapy* (ECT) in OCD (Fontenelle 
et al., 2015). Hence, ECT may be recommended only for 
acute treatment of comorbid conditions such as depres-
sion or psychosis*.
To summarize, LF-rTMS delivered over the SMA (with 
figure-8 coil) and HF-deep-rTMS over the dorsomedial 
prefrontal cortex/anterior cingulate cortex (with H7 coil) 
appear promising interventions in treatment-resistant 
OCD. There is a pressing need for large replication stud-
ies and evaluation of long-term effects/maintenance pro-
tocols. The evidence for tDCS is highly preliminary and 
further exploratory studies are encouraged.
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Treatment-resistant obsessive-compulsive 
disorder – deep brain stimulation and 
ablative neurosurgery
A significant number (10–40%) of patients do not 
respond to any available therapy and suffer from severe, 
enduring symptoms and dysfunction (Fineberg and Gale, 
2005; Denys, 2006; Gupta et al., 2019). For this highly 
refractory patient group, ablative neurosurgery* and 
deep brain stimulation* (DBS) remain modalities to be 
considered. These procedures are usually delivered as 
an adjunct to existing pharmacological treatments, and 
CBT is frequently also administered, either during the 
acute treatment phase or follow-up. DBS is considered an 
experimental treatment, but has an FDA ‘humanitarian 
device exemption’ for severe refractory OCD (US Food 
and Drug Administration, 2009).
Stereotactic neurosurgical procedures for intractable 
OCD have been available for >50  years (Miguel et al., 
2019). The procedures include dorsal anterior cingulot-
omy and anterior capsulotomy and are reserved for the 
most severe, treatment nonresponsive patients. A sys-
tematic review involving 10 studies and 193 participants 
suggested both procedures were efficacious (Brown et al., 
2016). The authors reported a mean Y-BOCS reduction 
of 37% for cingulotomy and 57% for capsulotomy. The 
rates of serious or permanent adverse events were 5.2% 
in the cingulotomy studies and 21.4% in the capsulotomy 
studies. Another recent review of publications on anterior 
capsulotomy spanning over five decades (Pepper et al., 
2019) reported ‘significant clinical response’ in 73–90% of 
patients and ‘remission’ in 24–39% of patients with treat-
ment-resistant OCD.
DBS was investigated as a partially reversible alterna-
tive to surgical ablation (Nuttin et al., 1999). The original 
stimulation target was similar to the site of anterior cap-
sulotomy, that is, ventral capsule/ventral striatum (VC/
VS). Three reasonably sized studies have provided evi-
dence in favour of the acute efficacy of DBS in the VC/
VS. The first involved 24 patients who were followed 
up to four years and reported a 37% median improve-
ment in baseline Y-BOCS scores (Luyten et al., 2016). 
‘ON’ phases of stimulation were compared with ‘OFF’ 
phases (no stimulation), demonstrating that improve-
ments were unlikely to represent ‘placebo’ effects. The 
second study investigated 16 patients, initially as open 
label, reporting a 46% reduction in baseline Y-BOCS 
at 8 months as well as a significant difference (25%) in 
Y-BOCS scores when compared with sham stimulation 
in a subsequent month-long double-blind phase (Denys 
et al., 2010). A recent 12-month multicentre study of 
30 patients given VC/VS DBS (Menchón et al., 2019) 
reported a mean reduction of baseline Y-BOCS of 42%. 
Sixty percent of patients were responded (reduction in 
baseline Y-BOCS > 40%).
The long-term benefits of VC/VS DBS are less certain. An 
open-label follow up study of 10 patients (Greenberg et al., 
2006) reported a reduction in mean Y-BOCS from 34.67 
at baseline (severe) to 22.37 (moderate) at 36 months. In 
addition, significant improvements in global functioning, 
depression and anxiety persisted.
The anteromedial subthalamic nucleus (amSTN) has 
been identified as another promising target for DBS 
in OCD. Sixteen patients were randomized according 
to a crossover design to either 3 months active or sham 
treatment, resulting in a significantly greater reduction 
in mean Y-BOCS in the stimulation versus sham group 
(endpoint 19 ± 8 versus 28 ± 7) (Mallet et al., 2008). It 
remains unclear whether VC/VS holds any advantage 
over amSTN DBS. A recent ‘mechanism of effect’ study 
of six OCD patients, in which electrodes were implanted 
in both these sites, found differential improvements in 
mood (VC/VS) and cognitive flexibility (amSTN), sug-
gesting that DBS exerts therapeutic effects at these tar-
gets via different brain networks (Tyagi et al., 2019).
There have been no head-to-head trials compar-
ing ablative neurosurgery with DBS. A recent review 
(Pepper et al., 2015) retrospectively evaluated 20 
studies of varying methodological quality involving 
62 patients who underwent DBS of the VC/VS or the 
nucleus accumbens and 108 patients who underwent 
anterior capsulotomy. The capsulotomy group showed 
a significantly higher (51%) mean reduction in Y-BOCS 
than the DBS group (40%). No difference in surgical 
complication rates was observed. Adverse events across 
both modalities included intracranial haemorrhage 
(2–5%), persisting postoperative side effects (5–7%), 
cognitive and personality changes (7–13%) and suicide 
(1–2%). Weight gain (defined by an increase >10%) was 
significantly higher in the capsulotomy group (29 ver-
sus 3%). In other studies (Mallet et al., 2008; Menchón 
et al., 2019), hypomania after electrode implantation is 
commonly (6%) reported.
In summary, studies of both DBS and ablative neurosur-
gery have shown these techniques are clinically effec-
tive for this highly refractory and extremely chronically 
disabled patient group. However, there is as yet insuffi-
cient evidence to determine which technique to choose 
at an individual patient level. Further clarification of the 
differential effects of ablation and stimulation across 
the different candidate neural targets, as well as better 
understanding of the interaction between somatic, phar-
macological and psychological interventions, have the 
potential to advance the field towards a personalized 
approach. Agreement over standardized patient selection 
and treatment protocols that would allow clinical out-
comes data to be collected and compared across treatment 
centres, represents an achievable milestone towards this 
goal (Menchón et al., 2019). Meanwhile, technological 
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innovations, for example, MRI-guided focussed ultra-
sound, laser interstitial thermal therapy (Miguel et al., 
2019), offer potential for safer and more cost-effective 
surgical approaches.
Future directions for research
Problematic usage of the internet
Problematic use of the internet (PUI) is an umbrella 
term for a range of repetitive functionally impairing com-
pulsive behaviours including gambling, gaming, sexual 
behaviour, shopping, video-streaming or social media use. 
While advances have been made in defining diagnostic 
criteria and developing rating scales for some forms of 
PUI (e.g., Gaming Disorder) (Király et al., 2015), a consid-
erable amount of research is needed to understand bet-
ter the broad range of PUI phenomena and translate the 
known behavioural phenotypes into valid and reliable 
diagnostic criteria and assessment tools, to facilitate the 
systematic investigation of aetiological factors and brain-
based mechanisms, as a platform for the development of 
preventive and therapeutic interventions (Fineberg et al., 
2018c).
Significant cross-sectional associations between PUI and 
OCD symptoms have been found (Carli et al., 2013). 
For example, in a two-site international online survey, 
ADHD and social anxiety disorder were associated with 
high PUI scores in young participants, whereas OCD and 
generalized anxiety disorder were associated with high 
PUI scores in older participants (Ioannidis et al., 2018).
Novel digital interventions in obsessive-compulsive 
disorder
Digital technology offers new opportunities for monitor-
ing and interventions. The extensive use of smartphones 
and the vast amounts of information they contain has 
positioned them as a proxy for behavioural and social 
interactions (WHO, 2016). Harnessing smartphone tech-
nology along with smart wearables (e.g., smart watches) 
is expected to be a valuable source of continuous, objec-
tive and reliable data for clinical characterization, behav-
ioural monitoring and treatment support (Marzano et al., 
2015). This is true for several disorders, but especially 
true for obsessive-compulsive problems such as PUI, as 
the digital media that is directly linked to the disorder is 
the same one that can accurately monitor the behaviour 
(Ferreri et al., 2019).
Accordingly, using digital technology along with big data 
analyses may enable the potential to characterize the ‘dig-
ital phenotype’ of the disorder (Ferreri et al., 2019) and 
to identify those individuals most at risk (e.g., by moni-
toring online internet usage in comparison with changes 
in diurnal variation, lack of human contact, lack of geo-
graphical movement, restricted circles of friends, etc.). 
A research avenue in this direction is to use (real time) 
big data analysis, alongside machine learning algorithms, 
to establish identifiable OCRD-specific illness patterns 
and use those real-time results to create an immediate 
feedback loop with the patient, which could then be used 
therapeutically by providing direct feedback on their 
behaviour and progress.
Other forms of active online intervention have become 
increasingly available for OCRD (Whiteside et al., 2013) 
and may potentially enhance and facilitate treatment 
adherence (Andersson et al., 2014; Marzano et al., 2015). 
For example, WhatsApp group interventions, in which 
the patient reports to their clinician, in real time, their 
difficulties, daily achievement and progress, enable 
continual communication, real-time reporting, prompt 
responses and rapid intervention when needed. In addi-
tion, the digital intervention may serve as a platform for 
continuous monitoring of tasks delivered in face-to-face 
meetings. Another example of existing digital interven-
tions is the proactive use of webcams and smartphone 
cameras. Using this domain and with patient’s consent, 
the clinician has the opportunity to monitor patients in 
their natural environment. As the digital platform bridges 
the elapsed time between therapeutic sessions, it over-
comes geographical distances and enables therapeutic 
practice in the patient’s natural environment (WHO, 
2016), where symptoms are manifested daily. In addition 
to enriching the clinical picture by direct observation of 
symptoms, it confers the general assertive outreach ben-
efits of telemedicine, which can be critical for otherwise 
difficult to treat socially isolated patients who cannot 
access help otherwise.
In practice, this approach breaks down the traditional 
terminology of ‘outpatient’, ‘in-patient’ and ‘day hospi-
talization’, by allowing real time, objective and continu-
ous monitoring (WHO, 2016). The combination of digital 
monitoring and online communication produces a form 
of ‘virtual hospitalization’, enabling comprehensive and 
intensive treatment by offering continued monitoring 
and delivery of therapy in the patient’s natural environ-
ment, where the OCD usually occurs, and not within the 
artificial setting of the clinic. While such approaches are 
still under development, digital tools seem to bear great 
potential and may change the landscape of treatment in 
OCRDs, providing potentially cost-effective alternatives 
to hospitalization or outpatient clinics.
Immunological therapies
Inflammation and release of inflammatory cytokines affect 
brain circuitry involving both reward and threat-sensitiv-
ity, producing potentially adaptive and beneficial behav-
ioural responses (Raison and Miller, 2013). There is 
growing evidence of dysfunctional immunological func-
tion in the pathogenesis of a significant subset of OCD 
patients. Elevated levels of basal ganglia antibodies have 
been detected in adult OCD patients’ plasma compared 
with psychiatric control groups (Nicholson et al., 2012). In 
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addition, significantly increased levels of CSF autoanti-
bodies directed against basal ganglia and thalamus were 
found among drug-naive OCD patients, and were asso-
ciated with increased levels of CSF glutamate and gly-
cine, indicating underpinning abnormalities in excitatory 
neurotransmission and correlating with hyperactivity in 
the ventral cognitive circuit (Bhattacharyya et al., 2009). 
Translocator protein distribution volume, a marker of the 
microglial component of neuroinflammation, was found 
to be significantly elevated in the CSTC circuit of OCD 
subjects compared with healthy controls, demonstrat-
ing inflammation within the neurocircuitry extending 
beyond the basal ganglia, and affecting the adult popu-
lation rather than solely childhood OCD (Attwells et al., 
2017).
A common genetic link may explain an excess of some 
autoimmune comorbidities. For example, in the acute 
paediatric onset subset of children (PANDAS), there is 
immunological cross-reactivity with epitopes associated 
with streptococcal infection expressed on the surface of 
basal ganglia neurons. About 20% of the mothers of chil-
dren fulfilling criteria for PANDAS (Chang et al., 2015) 
had at least one autoimmune disease. Multigenerational 
studies also show that OCD patients’ relatives are more 
likely to have an autoimmune disease such as Sjögren’s 
syndrome, coeliac disease, Guillian Barrè, Crohn’s dis-
ease, Hashimotos Thyroiditis, type I diabetes mellitus, 
ulcerative colitis, multiple sclerosis and psoriasis vul-
garis (Mataix-Cols et al., 2018). A subset of patients with 
PANDAS with motor symptoms demonstrated antineu-
ral antibodies against dopamine (D1) receptors as well 
as elevated antibodies against tubulin, lysoganglioside 
and higher activation of calmodulin-dependent protein 
kinase II (Cox et al., 2015).
Immunomodulatory therapy represents a new field of 
investigation in OCD. While treatment with antimi-
crobials has delivered inconsistent results (Burchi and 
Pallanti, 2018), other immunological modulators, such as 
celecoxib* (Shalbafan et al., 2015) and nonspecific non-
steroidal anti-inflammatory drugs (Spartz et al., 2017), 
have produced some positive findings, the latter only 
in a subset of young people. Thus, evidence of the use-
fulness of this approach in OCD remains insufficient. 
Nevertheless, researchers and clinicians should consider 
genetic and immunological profile differences in the 
search for precise individualized therapy for OCD.
Novel forms of psychotherapy
Although it may seem logical to try to tackle OCD using 
cognitive therapy, little evidence suggests that it offers 
any advantage to graded exposure and self-imposed 
response prevention (Tyagi et al., 2010; Ougrin, 2011). 
Poorly applied cognitive therapy, such as that expecting 
patients to re-evaluate actual dangers, may make some 
patients with OCD worse. This is because the process of 
looking for evidence to confirm or refute the obsessions 
can become incorporated into rituals. Cognitive therapy 
may also turn out to be less cost-efficient, as it requires 
more training and supervision for the therapist and usu-
ally takes more time in therapy. It is therefore probably 
best used in situations where there is OCD refractory to 
ERP therapy (Drummond and Edwards, 2018).
Rational emotive therapy, on the other hand, has been 
shown to have some possible beneficial effects in OCD 
(Emmelkamp et al., 1988). Australian researchers have 
developed danger ideation reduction therapy (DIRT), 
using rational emotive therapy but with instructions 
not to undergo exposure for patients with contamina-
tion fears; good outcomes in case reports and some small 
controlled trials have been found (Jones and Menzies, 
1998; Krochmalik et al., 2001; Maqbool et al., 2017). The 
techniques used in DIRT include cognitive restructur-
ing using rational emotive therapy (Ellis, 1962); filmed 
interviews with people who work in feared situations; 
corrective information about the real risks of ‘contami-
nation’ as opposed to the deleterious effects of overzeal-
ous hand-washing and attentional focussing whereby 
patients are taught to focus the mind away from the dan-
ger-related intrusive thoughts.
In recent years, the so-called Third Wave Therapies have 
been used in a number of psychiatric conditions (Pérez 
Álvarez, 2012). The therapy of this type most commonly 
used in OCD is mindfulness, which teaches an individ-
ual to focus on the world around them rather than their 
internal dialogue. A recent study demonstrated that 
both cognitive restructuring and also mindfulness led to 
a small improvement in Y-BOCS score when compared 
with waiting list controls. However, the strength of effi-
cacy for both treatments appeared to be less than that 
generally found with ERP (Rupp et al., 2019). Despite 
promising results for metacognitive therapy in patients 
with OCD in case series, a full controlled trial has yet to 
be performed (Melchior et al., 2019).
Many OCD patients describe their compulsions as habit-
ual, that is, fixed ‘stimulus-response ’acts that, through 
habit learning, occur automatically in response to a 
specific environmental trigger. Habit reversal therapy 
(HRT) (Azrin and Nunn, 1973) is a long-established 
form of therapy that helps patients alter habitual perfor-
mance through a variety of behavioural methods. HRT is 
reported to be efficacious for the treatment of Tourette 
syndrome and Tic Disorders and has more recently been 
applied with success in OCRDs such as trichotillomania 
and skin picking behaviours. However, there remains 
a scarcity of evidence from controlled trials to support 
the efficacy of HRT in OCRDs in general and OCD in 
particular (Lee et al., 2019a). Emerging neurosciences 
evidence identifying faulty habit learning in OCD 
(Fineberg et al., 2018a) suggests further study of HRT in 
OCD would be worthwhile.
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Pharmacogenetics
Pharmacogenetics or pharmacogenomics define genetic 
variants that influence either drug metabolism, delivery, 
affinity to receptors or transporters may contribute to the 
prediction of drug efficacy or toxicity, promoting preci-
sion medicine (Hess et al., 2015). Because approximately 
one-quarter of OCD patients do not respond to treatment 
with either SSRIs or CBT alone, or their combination 
(Hirschtritt et al., 2017), it has been suggested that phar-
macogenetics may contribute to better drug-response 
prediction and side effect tolerance (Zai et al., 2014).
Currently, several pharmacogenetic approaches using 
hypothesis-free GWAS have been conducted into the 
association between candidate genes and drug response in 
OCD patients (Di Bella et al., 2002; Denys et al., 2007; Van 
Nieuwerburgh et al., 2009; Miguita et al., 2011; Grünblatt 
et al., 2014; Zai et al., 2014; Umehara et al., 2015; Mas et al., 
2016; Qin et al., 2016; Umehara et al., 2016; Taj et al., 2018; 
Lisoway et al., 2018; Sina et al., 2018; Abdolhosseinzadeh 
et al., 2019a,b; Alizadeh et al., 2019). The candidate 
genes investigated belong to: (1) pharmacokinetic regu-
lating genes, such as the CYP450 liver enzymes such as 
CYP2D6 and CYP2C19; (2) serotonergic systems, such as 
SLC6A4 and its promoter, HTTLPR, HTR2A, HTR2C, 
HTR1B and TPH2; (3) glutamatergic systems, such as 
SLC1A1, DLGAP2, DLGAP2, GRIN2B, GRIK2, SLIT, 
SLITRK5; (4) dopaminergic systems, such as COMT, 
MAOA, DRD2 and DRD4 and (5) other systems, such as 
BDNF, NTRK3, MOG, OLIG2 and DISP1.
Currently, no consensus with sufficiently robust results 
exists in the pharmacogenetics of OCD, due to the fact 
that many studies used naturalistic approaches, did not 
employ double blinded designs or crossed over with the 
tested drug, used a variety of drugs and doses, as well as 
used various cutoffs and measures determining response. 
Although there is still a need systematically to assess the 
pharmacogenetic link between treatment response (to 
SSRIs, tricyclics, antipsychotics, clomipramine, etc.) and 
certain genes, some data are already available, though very 
limited, on the Internet (e.g., https://www.pharmgkb.org; 
Whirl-Carrillo et al., 2012) summarizing some findings on 
pharmacogenetics of some drugs and giving some recom-
mendations aligning with those of the FDA, European 
Medicine Agency, Pharmaceutical and Medical Devices 
Agency, Japan and Health Canada (Sante Canada).
Conclusion
Until just 40 years ago, OCD was considered rare, of psy-
chological origin and without effective treatment. Now, all 
have changed; the finding in the 1970s and 1980s that ser-
otonergic medication (clomipramine, followed by SSRIs) 
was effective (Montgomery, 1980; Zohar et al., 1987; 
Zohar and Insel, 1987) opened the door to great inter-
est in OCD (Zohar, 2012). This led to the development 
of specific forms of psychological intervention (ERP) 
which replaced the dynamic approach and to a focus 
on the serotonergic system in the treatment and patho-
physiology of OCD. As a result of neuroscience insights 
including endophenotype-based approaches (reviewed 
in Fineberg et al., 2018a), OCD has been removed from 
the anxiety disorder grouping in the DSM-5 (American 
Psychiatric Association, 2013) and ICD-11 (WHO, 2018) 
and now stands at the head of a new family of OCRDs.
The realization that OCRDs as a group are different from 
other anxiety disorders has led to significant changes in 
understanding their impact (the prevalence of OCRD in 
the population is more than 9%) (Carmi et al., 2019, in 
submission) and to refinement of the treatment approach 
(e.g., focussing on the urge to perform compulsions and 
the need for higher doses of serotonergic medication).
This position statement highlights the major changes 
that have been taking place in the last few years in the 
field of OCD, in terms of conceptualization, diagnosis, 
assessment, intervention (with focus on early interven-
tion), strategies for optimizing the efficacy of specific 
pharmacological intervention (SRI) with specific psycho-
logical intervention (ERP), the critical role of treatment 
of children and young adults and the importance of main-
tenance of well-being.
As new neuroscience insights are revealed, new thera-
peutic interventions are being explored (e.g., glutamater-
gic agents, dopaminergic modulators, etc.). This position 
statement also covers invasive and noninvasive neuro-
modulation as experimental interventions, including 
deep TMS (achieving FDA indication for OCD in 2018) 
(US Food and Drug Administration, 2018).
Looking to the future, other exciting avenues for inves-
tigation include the use of digital tools to monitor (and 
eventually to diagnose OCRDs), better understanding 
of links between excessive Internet use and OCRDs, 
advanced genetic methods and new pharmacological 
domains (e.g., immunological systems). Indeed, it seems 
that the future was never so bright for OCRD patients. 
We trust that this position statement has managed to cap-
ture, describe, explain and shed light on many of these 
developments, including those in the front line of under-
standing and treatment of OCRD in the future.
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